EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies

Dorian Yarih García-Ortega iD, Gabriela Alamilla-García iD, Kevin Fernando Reyna-Pérez iD, Jessica Baldriche-Acosta, Luis Alonso Herrera-Montalvo iD, Carlo César Cortés-González iD

Cancers · 22.07.2026 · 18 (14) · 2364

DOI: 10.3390/cancers18142364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.07.2026. Verfasst von Dorian Yarih García-Ortega und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Cirugía Oncológica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Sciences, Humanities, Technology and Innovation, Secretaría de Ciencia, Humanidades, Tecnología e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Soft tissue sarcomas are rare, biologically diverse mesenchymal malignancies in which pharmacologic resistance cannot be explained by a single unifying mechanism. In this narrative review, resistance is conceptualized as a dynamic, multilayered process shaped by histologic subtype, genomic architecture, transcriptional plasticity, the tumor microenvironment, and treatment-driven selective pressure. Resistance to conventional chemotherapy arises through both intrinsic and acquired mechanisms, including altered drug transport and metabolism, enhanced DNA damage responses, impaired apoptotic signaling, clonal selection, and the emergence of therapy-persistent cellular states. By contrast, resistance to targeted and epigenetic therapies more often reflects adaptive bypass signaling, lineage reprogramming, and incomplete identification of subtype-specific dependencies than secondary on-target alterations alone. The tumor microenvironment further contributes to therapeutic failure through hypoxia, extracellular matrix-mediated barriers, abnormal vascularization, myeloid-dominant immunosuppression, and immune exclusion, thereby helping explain the modest and histology-dependent activity of immune checkpoint inhibitors in soft tissue sarcoma. This review also differentiates baseline predictive biomarkers from dynamic resistance-monitoring tools, underscoring the potential—despite still limited clinical maturity—of pharmacogenomic markers, immune signatures, tertiary lymphoid structures, circulating tumor DNA, and circulating methylation-based approaches. Finally, emerging strategies to overcome resistance are examined, including mechanism-based combinations, biomarker-guided treatment selection, synthetic lethality, functional precision platforms, and adaptive histology-specific trial designs. Collectively, these observations support a view of resistance in soft tissue sarcoma as a context-dependent biological process that demands integrated, subtype-aware, and translationally grounded therapeutic strategies.

Schlagwörter

Stichwörter der Autor:innen

biomarkersdrug resistanceimmunotherapyliquid biopsyprecision oncologysoft tissue sarcomatargeted therapytumor microenvironment

Autor:innen und Institutionen

  • Departamento de Cirugía Oncológica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
  • Departamento de Oncología Médica, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.
  • Secretaría del Medio Ambiente de la Ciudad de México (SEDEMA), Ciudad de Mexico 06060, Mexico.
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de Mexico 14250, Mexico.
  • Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Ciudad de Mexico 14380, Mexico.
  • Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Ciudad de Mexico 14080, Mexico.

ORCID-Profile: Dorian Yarih García-Ortega, Gabriela Alamilla-García, Kevin Fernando Reyna-Pérez, Luis Alonso Herrera-Montalvo, Carlo César Cortés-González

Förderung

  • Ministry of Sciences, Humanities, Technology and Innovation
  • Secretaría de Ciencia, Humanidades, Tecnología e Innovación

Zitieren

APA

García-Ortega, D. Y., Alamilla-García, G., Reyna-Pérez, K. F., Baldriche-Acosta, J., Herrera-Montalvo, L. A., & Cortés-González, C. C. (2026). Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies. Cancers, 18(14), 2364. https://doi.org/10.3390/cancers18142364

Vancouver

García-Ortega DY, Alamilla-García G, Reyna-Pérez KF, Baldriche-Acosta J, Herrera-Montalvo LA, Cortés-González CC. Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies. Cancers. 2026;18(14):2364. doi:10.3390/cancers18142364

BibTeX
@article{GarcaOrtega2026,
  author = {García-Ortega, Dorian Yarih and Alamilla-García, Gabriela and Reyna-Pérez, Kevin Fernando and Baldriche-Acosta, Jessica and Herrera-Montalvo, Luis Alonso and Cortés-González, Carlo César},
  title = {Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2364},
  doi = {10.3390/cancers18142364}
}
Kostenlos starten →